Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ocrevus
Pharma
Zenas gains MS hopeful in $2B deal with China's InnoCare
Eying an MS drug with potential peak sales projections of $12B, Zenas has struck a licensing deal with InnoCare that could be worth more than $2B.
Kevin Dunleavy
Oct 8, 2025 11:50am
What's on neurologists' minds? Not drug names, survey shows
Jul 18, 2025 10:10am
Roche's high-dose version of Ocrevus flunks phase 3 trial
Apr 2, 2025 3:26pm
MS meds send CNS market toward strongest growth in years
Mar 26, 2025 10:48am
Roche's Vabysmo will rise above Eylea biosim threat, exec says
Oct 23, 2024 11:24am
Roche doubles down with subcutaneous FDA nod for MS star Ocrevus
Sep 13, 2024 1:50pm
